课题基金 / 基金详情

Phenotypic Viability Screening using Thyroid Cancer Cells

Phenotypic Viability Screening using Thyroid Cancer Cells
使用甲状腺癌细胞进行表型活力筛查
批准号:
9205667
负责人:
Min Shen
金额:
$1.9万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Min Shen的其他基金

相似基金

相关文献

中文摘要
翻译
项目要点:对表型活性筛选进行了优化和执行,并选择了HITS进行二次表征和后续研究。 在此期间,NCGC与NIH和校外调查人员进行了180多次积极的合作,促进了整个人类疾病范围内的药物发现工作。这些努力已经产生了100多个高通量筛选和近60个药物化学活动,为我们的合作者和一般研究社区提供了丰富的出版物和前景光明的小分子线索。此外,NCGC还承担了一些信息学挑战,以更好地利用现有的药物和疾病目标信息,并为公众提供易于获取的资源,进一步催化人类疾病新疗法的开发。
英文摘要
Project highlights: phenotypic viability screens were optimized and executed, and hits were chosen for secondary characterization and followup. During this period, the NCGC has fostered and maintained over 180 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to over 100 high-throughput screens and nearly 60 medicinal chemistry campaigns, providing our collaborators and the general research community a wealth of publications and promising small molecule leads. In addition, the NCGC has undertaken a number of informatic challenges to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
qHTS for Inhibitors of Vif-A3F Interactions
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents
qHTS for Inhibitors of Vif-A3G Interactions
Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia
海外基金